SERVICES RESEARCH ON THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK
Release Date: September 6, 2000
RFA: DA-01-003
National Institute on Drug Abuse
(http://www.nida.nih.gov)
Letter of Intent Receipt Date: November 20, 2000
Application Receipt Date: December 19, 2000
BOTH MODULAR AND NONMODULAR GRANT APPLICATIONS MAY BE SUBMITTED IN RESPONSE
TO THIS RFA. FOR MODULAR GRANTS, THE "JUST-IN-TIME" CONCEPT IS USED, AND
THERE ARE DETAILED MODIFICATIONS TO STANDARD APPLICATION INSTRUCTIONS THAT
MUST ALSO BE USED WHEN PREPARING APPLICATIONS IN RESPONSE TO THIS RFA. FOR
NONMODULAR APPLICATIONS (APPLICATIONS HAVING AT LEAST ONE YEAR"S REQUESTED
DIRECT COSTS EXCEEDING $250,000), THE MODIFIED INSTRUCTIONS FOR MODULAR
GRANTS AND JUST-IN-TIME PROCEDURES ARE NOT USED, AND THE TRADITIONAL PHS 398
INSTRUCTIONS SHOULD BE FOLLOWED INSTEAD.
PURPOSE
This Request for Applications (RFA) encourages (a) research on changes in
clinical management and organizational practices of community treatment
providers participating in the National Institute on Drug Abuse’s National
Drug Abuse Treatment Clinical Trials Network (CTN), (b) research to improve
the ability of non-network providers to adopt new research-based treatments,
and (c) research on the cost-effectiveness of treatments tested in the CTN
compared with typical treatment. Research on other health services issues
related to the CTN and its overarching goal to improve drug abuse treatment
nationwide is also encouraged.
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2010," a PHS-
led national activity for setting priority areas. This RFA is related to one
or more of the priority areas. Potential applicants may obtain a copy of
"Healthy People 2010" at http://www.health.gov/healthypeople/.
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic for-profit and nonprofit
organizations, public and private, such as universities, colleges, hospitals,
laboratories, units of state and local governments, and eligible agencies of
the Federal government. Racial/ethnic minority individuals, women, and
persons with disabilities are encouraged to apply as Principal Investigators.
MECHANISM OF SUPPORT
This RFA will use the National Institutes of Health (NIH) research project
grant (R01) award mechanism. Responsibility for the planning, direction, and
execution of the proposed project will be solely that of the applicant. The
total project period for an application submitted in response to this RFA may
not exceed five years. This RFA is a one-time solicitation. Future
unsolicited competing continuation applications will compete with all
investigator-initiated applications and be reviewed according to the
customary peer review procedures. The anticipated award date is July 2001.
FUNDS AVAILABLE
NIDA intends to commit approximately $2.0 million in FY 2001 to fund up to
five new and/or competitive continuation grants in response to this RFA. The
level of support is dependent upon the receipt of a sufficient number and
diversity of applications of high scientific merit. Because of the nature
and scope of the research proposed, it is anticipated that the size of an
award will also vary. Although the financial plans of NIDA provide support
for this program, awards pursuant to this RFA are contingent upon the
availability of funds and the receipt of a sufficient number of meritorious
applications. At this time, it is not known if this RFA will be reissued.
RESEARCH OBJECTIVES
This RFA encourages research on health services issues related to the
National Drug Abuse Treatment Clinical Trials Network (CTN). Specific areas
of research focus include studies on the process of change in clinical
practices and organizational processes and structures of community treatment
providers participating in the CTN, research on the effectiveness of
strategies to help non-network providers adopt new research-based treatments,
and research on economic issues related to treatments being tested in the
CTN.
Background
The potential public health benefit of new behavioral and pharmacological
treatments for drug abuse has not been fully realized because many providers
have not adopted these new treatments. In 1999, the National Institute on
Drug Abuse (NIDA) established the National Drug Abuse Treatment Clinical
Trials Network, a cooperative research program to conduct coordinated multi-
site clinical trials of behavioral and pharmacological therapies for drug
abuse and addiction. Funded under RFA 99-004, the CTN presently consists of
six nodes representing the Delaware Valley, Mid-Atlantic, New England, New
York, Pacific Northwest, and West Coast regions. Each node consists of a
regional research and training center, all currently based in academic
institutions, and five or more participating community treatment providers.
Plans call for the addition of new community treatment providers in each
node. Additionally, the CTN is expected to be expanded in fiscal year 2000
by the addition of up to six more nodes, and further nodes may be added in
the future.
The CTN’s overarching goal is to improve the quality of drug abuse treatment
in the nation by conducting clinical trials to test behavioral and
pharmacological therapies for a broad range of patients in a variety of
clinical settings, and by finding ways to integrate these tested medications
and behavioral interventions into mainstream clinical practice. In addition,
the CTN is expected to provide an infrastructure and a platform to research
other questions relevant to the improvement of community-based treatment
practice.
References made in this RFA to "CTN-tested treatments" include treatment
interventions being tested in the CTN as well as those under consideration in
the CTN. In addition, studies may be proposed using science-based, effective
interventions similar to those being tested in the CTN if the research
focuses on processes or models that are not dependent upon a specific
treatment intervention.
I. Organizational and Practitioner Adaptation and Change in CTN Community
Treatment Providers and in Other Community Treatment Providers
Adopting new treatment methods into clinical practice, be they
pharmacological or behavioral in nature, involves change at both the
organizational and practitioner levels. The introduction of new treatment
approaches into an existing provider organization may require adaptation of
clinical and business practices to sustain treatment advances over the longer
term. There has been little research to understand organizational adaptation
and change by organizations or practitioners in the drug abuse treatment
system, with the consequence that little is known about the processes by
which change occurs or how to facilitate change to improve the overall
quality of drug abuse treatment.
Understanding the process of adaptation and change includes research in the
areas of organizational culture, readiness and motivation for organizational
change, and change management and follow-through. Research is needed to
understand the process of change with regard to how treatments being tested
in the CTN can be successfully assimilated by the treatment organizations,
including:
- adoption of behavioral and pharmacological therapies tested in clinical
trials by community treatment providers, and effective models and practices
to plan and manage such adoption,
- readiness and capacity to successfully adopt new treatment methods,
- business practices that increase motivation for change and improvement,
and
- effects of change in clinical and business practices on organizational
climate and culture, particularly with regard to innovation in clinical
practices.
Organizational culture. Sustained change in clinical practice may require
reframing of the organizational culture to accommodate new values, beliefs,
and therapeutic and business practices. The reframing process can include
altering organizational structures, modifying fiscal and resource management
procedures, acquiring new job skills, revising treatment philosophies,
renegotiating the nature of linkage relationships, or revising staff and
client interactions. Research is needed to determine how participation in
the CTN may improve the quality of drug abuse treatment services and outcomes
through changes in organizational culture or changes in therapeutic and
business practices.
Capacity and motivation for change. Adoption of research-based treatments
require that organizations have the capacity to change. Barriers to adoption
include lack of needed resources, philosophical resistance toward the
research-based treatment, resistance from clientele or payers, or lack of
time to plan and implement change. Research is sought to improve the
organization’s capacity for change.
Although workforce consensus for change may result from crisis, current
organizational theory suggests that effective change results from a routine,
normative practice of continuous improvement of services and products.
Continuous improvement efforts might include outreach to other community
providers, client focus groups, or partnerships between staff and management.
Research is sought on how organizations effectively learn and adopt
techniques or methods needed to effect change, such as benchmarking, formal
training, attending workshops or conferences, and other approaches to
identify promising clinical and business practices.
Change management and follow-through. Research is sought on the processes
needed for successful adoption of a new treatment after the decision to adopt
has been made. These processes may include planning, implementing, and
managing change, as well as monitoring to ensure that anticipated benefits
are realized and that quality of services is maintained. Research is needed
on the application of systematic knowledge of how to plan and manage change
and how to monitor processes to insure that changes in business practices are
sustained. Research on change management may include studies of the effects
of improved management information systems or improved decision-making
procedures on treatment performance.
II. Effective Strategies to Help Non-Network Providers Adopt New Research-
Based Treatments
Although non-network treatment providers do not receive training or financial
research incentives to implement new treatment technologies, they are under
the same competitive pressures as CTN providers to improve their clinical and
business practices in order to provide effective and efficient drug abuse
treatment. While the research infrastructure of the CTN promotes short-term
adoption of new treatment approaches, research is needed in the area of
organizational change to support long-term adoption of treatment technologies
found effective in the CTN.
Research is encouraged to develop and test models for integrating new CTN-
tested interventions into existing clinical practices, including studies on
levels of theoretical and practical knowledge needed by practitioners, how to
assess patient need for the new intervention, how the new treatment is staged
or incorporated into an ongoing treatment regimen, how to measure program
performance, outcomes, and cost-benefits for the new intervention, and how to
integrate the new treatment with linked services. Areas of research interest
include:
- strategies to effectively transport CTN-tested treatment interventions
into clinical practice,
- organizational or management strategies or processes to improve
transmission of knowledge, adaptation of new treatments, and their adoption
into widespread clinical practice,
- enhancements to technology transfer methods and mechanisms,
- improvements of existing mechanisms to facilitate adoption of treatment
approaches, such as research to improve the capability of Addiction
Technology Transfer Centers, funded by the Substance Abuse and Mental Health
Services Administration’s Center for Substance Abuse Treatment, to
disseminate CTN-tested treatments beyond the network.
III. Economic Research on Treatments Being Tested in the CTN
Economic research on drug abuse treatment services informs decisions related
to the allocation of resources and the desire to enhance efficiency and
equity. Whether CTN-tested treatment interventions will be adopted by
community treatment providers depends in part on whether these interventions
are covered by public or private payers. Research is needed on:
- Costs, including direct and indirect costs, of drug abuse services and
ancillary services, as well as studies on the component unit service costs of
drug abuse services to improve knowledge about full cost pricing of service
delivery for CTN-tested drug abuse treatments.
- Cost-benefit and cost-effectiveness analyses on innovative treatment
therapies and interventions in the CTN and in non-network treatment
providers.
- Cost savings (or "cost-offsets") resulting from CTN-tested treatments that
reduce or avert medical or social costs.
- Outcome measurement and monitoring to improve the quality and management
of resources.
- Impact of health plan parity benefits and managed care practices on
coverage of and access to CTN-tested treatments.
PARTICIPATION OF CTN INVESTIGATORS
Some research projects proposed under this RFA may require the participation,
collaboration, cooperation, or other support by CTN investigators or
community treatment provider staff or patients. Although the CTN is expected
to create a research infrastructure that will support studies such as those
encouraged here, some studies involving the CTN may not be feasible given the
mission, goals, and timetables of the CTN cooperative studies. It is
incumbent on the applicant to demonstrate that the support required of CTN
participants has been obtained so that the proposed project is feasible. The
use of data collected by the CTN is governed by rules established by the CTN
Steering Committee, so it is especially important to demonstrate the
feasibility of research proposing to use CTN-owned data. Information about
the CTN, including contact information, is available at
http://www.nida.nih.gov/ClinicalTrials.html.
INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of the NIH that women and members of minority groups and
their subpopulations must be included in all NIH supported biomedical and
behavioral research projects involving human subjects unless a clear and
compelling rationale and justification are provided indicating that inclusion
is inappropriate with respect to the health of the subjects or the purpose of
the research. This policy results from the NIH Revitalization Act of 1993
(Section 492B of Public Law 103-43).
All investigators proposing research involving human subjects should read the
UPDATED "NIH Guidelines for Inclusion of Women and Minorities as Subjects in
Clinical Research," published in the NIH Guide for Grants and Contracts on
August 2, 2000
(http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-048.html),
a complete copy of the updated Guidelines is available at
http://grants.nih.gov/grants/funding/women_min/guidelines_update.htm. The
revisions relate to NIH defined Phase III clinical trials and require: a)
all applications or proposals and/or protocols to provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable,
and b) all investigators to report accrual, and to conduct and report
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS
It is the policy of NIH that children (i.e., individuals under the age of 21)
must be included in all human subject research, conducted or supported by the
NIH, unless there are scientific and ethical reasons not to include them.
This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
NIH Policy and Guidelines on the "Inclusion of Children as Participants in
Research Involving Human Subjects" that was published in the NIH Guide for
Grants and Contracts, March 6, 1998, and is available at the following URL
address: http://grants.nih.gov/grants/guide/notice-files/not98-024.html.
Investigators also may obtain copies of these policies from the program staff
listed under INQUIRIES. Program staff may also provide additional relevant
information concerning these policies.
NATIONAL ADVISORY COUNCIL ON DRUG ABUSE RECOMMENDED GUIDELINES FOR THE
ADMINISTRATION OF DRUGS TO HUMAN SUBJECTS
The National Advisory Council on Drug Abuse recognizes the importance of
research involving the administration of drugs to human subjects and has
developed guidelines relevant to such research. Potential applicants are
encouraged to obtain and review these recommendations of the Council before
submitting an application that will administer compounds to human subjects.
The guidelines are available on NIDA"s Home Page at http://www.nida.nih.gov/
under Funding or may be obtained by calling (301) 443-2755.
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained within
specified page limitations. Unless otherwise specified in an NIH
solicitation, internet addresses (URLs) should not be used to provide
information necessary to the review because reviewers are under no obligation
to view the Internet sites. Reviewers are cautioned that their anonymity may
be compromised when they directly access an Internet site.
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes a
descriptive title of the proposed research, the name, address, and telephone
number of the Principal Investigator, the identities of other key personnel
and participating institutions, and the number and title of the RFA in
response to which the application may be submitted. Although a letter of
intent is not required, is not binding, and does not enter into the review of
a subsequent application, the information that it contains allows NIDA staff
to estimate the potential review workload and plan the review.
The letter of intent is to be sent to the following staff by the letter of
intent receipt date listed.
Director, Office of Extramural Affairs
National Institute on Drug Abuse
6001 Executive Blvd., Room 3158, MSC 9547
Bethesda, MD 20892-9547
Telephone: (301) 443-2755
FAX: (301) 443-0538
APPLICATION PROCEDURES
The research grant application form PHS 398 (rev. 4/98) is to be used in
applying for these grants. These forms are available at most institutional
offices of sponsored research and from the Division of Extramural Outreach
and Information Resources, National Institutes of Health, 6701 Rockledge
Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301) 710-0267, E-mail:
GrantsInfo@nih.gov.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
The modular grant concept establishes specific modules in which direct costs
may be requested, as well as a maximum level for requested budgets. Only
limited budgetary information is required under this approach. The just-in-
time concept allows applicants to submit certain information only when there
is a possibility for an award. It is anticipated that these changes will
reduce the administrative burden for the applicants, reviewers, and Institute
staff. The research grant application form PHS 398 (rev. 4/98) is to be used
in applying for these grants, with the modifications noted below:
BUDGET INSTRUCTIONS
Modular Grant applications will request direct costs in $25,000 modules, up
to a total direct cost request of $250,000 per year. (Applications that
request more than $250,000 direct costs in any year must follow the
traditional PHS 398 application instructions.) The total direct costs must
be requested in accordance with the program guidelines and modifications made
to the standard PHS 398 application instructions described below:
PHS 398
FACE PAGE - Items 7a and 7b should be completed, indicating Direct Costs (in
$25,000 increments up to a maximum of $250,000) and Total Costs [Modular
Total Direct plus Facilities and Administrative (F&A) costs] for the initial
budget period. Items 8a and 8b should be completed indicating the Direct and
Total Costs for the entire proposed period of support.
DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form Page 4
of the PHS 398. It is not required and will not be accepted with the
application.
BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete the
categorical budget table on Form Page 5 of the PHS 398. It is not required
and will not be accepted with the application.
NARRATIVE BUDGET JUSTIFICATION - Prepare a Modular Grant Budget Narrative
page. (See http://grants.nih.gov/grants/funding/modular/modular.htm for
sample pages.) At the top of the page, enter the total Direct Costs
requested for each year. This is not a Form page.
Under Personnel, list all project personnel, including their names, percent
of effort, and roles on the project. No individual salary information should
be provided. However, the applicant should use the NIH appropriation
language salary cap and the NIH policy for graduate student compensation in
developing the budget request.
For Consortium/Contractual costs, provide an estimate of total costs (Direct
plus F&A) for each year, each rounded to the nearest $1,000. List the
individuals/organizations with whom consortium or contractual arrangements
have been made, the percent effort of key personnel, and the role on the
project. Indicate whether the collaborating institution is foreign or
domestic. The total cost for a consortium/contractual arrangement is
included in the overall requested Modular Direct Cost amount. Include the
letter of intent to establish a consortium.
Provide an additional narrative budget justification for any variation in the
number of modules requested.
BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by
reviewers in the assessment of each individual"s qualifications for a
specific role in the proposed project, as well as to evaluate the overall
qualifications of the research team. A biographical sketch is required for
all key personnel, following the instructions below. No more than three
pages may be used for each person. A sample biographical sketch may be
viewed at: http://grants.nih.gov/grants/funding/modular/modular.htm.
- Complete the educational block at the top of the form page,
- List position(s) and any honors,
- Provide information, including overall goals and responsibilities, on
research projects ongoing or completed during the last three years, and
- List selected peer-reviewed publications, with full citations.
CHECKLIST - This page should be completed and submitted with the application.
If the F&A rate agreement has been established, indicate the type of
agreement and the date. All appropriate exclusions must be applied in the
calculation of the F&A costs for the initial budget period and all future
budget years.
The applicant should provide the name and phone number of the individual to
contact concerning fiscal and administrative issues if additional information
is necessary following the initial review.
The RFA label available in the PHS 398 (rev. 4/98) application form must be
affixed to the bottom of the face page of the application. Type the RFA
number on the label. Failure to use this label could result in delayed
processing of the application such that it may not reach the review committee
in time for review. In addition, the RFA title and number must be typed on
line 2 on the face page of the application form, and the YES box must be
marked.
The sample RFA label available at:
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf has been modified to
allow for this change. Please note this is in pdf format.
Submit a signed, typewritten original of the application, including the
Checklist, and three signed, photocopies, in one package to:
CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)
At the time of submission, two additional copies of the application must be
sent to:
Director, Office of Extramural Affairs
National Institute on Drug Abuse
6001 Executive Blvd., Room 3158, MSC 9547
Bethesda, MD 20892-9547
Rockville, MD 20852 (for express/courier service)
Applications must be received by the application receipt date listed in the
heading of this RFA. If an application is received after that date, it will
be returned to the applicant without review.
The Center for Scientific Research (CSR) will not accept any application in
response to this RFA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application. The
CSR will not accept any application that is essentially the same as one
already reviewed. This does not preclude the submission of substantial
revisions of applications already reviewed, but such applications must
include an introduction addressing the previous critique.
REVIEW CONSIDERATIONS
Upon receipt, applications will be reviewed for completeness by the CSR and
responsiveness by NIDA. Incomplete and/or non-responsive applications will
be returned to the applicant without further consideration.
Applications that are complete and responsive to the RFA will be evaluated
for scientific and technical merit by an appropriate peer review group
convened by NIDA in accordance with the review criteria stated below. As
part of the initial merit review, all applications will receive a written
critique and undergo a process in which only those applications deemed to
have the highest scientific merit, generally the top half of the applications
under review, will be discussed, assigned a priority score, and receive a
second level review by NIDA"s National Advisory Council.
Review Criteria
The goals of NIH-supported research are to advance the understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to discuss the following
aspects of the application in order to judge the likelihood that the proposed
research will have a substantial impact on the pursuit of these goals. Each
of these criteria will be addressed and considered in assigning the overall
score, weighting them as appropriate for each application. Note that the
application does not need to be strong in all categories to be judged likely
to have major scientific impact and thus deserve a high priority score. For
example, an investigator may propose to carry out important work that by its
nature is not innovative but is essential to move a field forward.
(1) Significance: Are the goals and objectives of this application
relevant to this RFA? Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? What will be the effect of these studies on the concepts or
methods that drive this field?
(2) Approach: Are the conceptual framework, design, methods, and analyses
adequately developed, well-integrated, and appropriate to the aims of the
project? Does the applicant acknowledge potential problem areas and consider
alternative tactics?
(3) Innovation: Does the project employ novel concepts, approaches, or
method? Are the aims original and innovative? Does the project challenge
existing paradigms or develop new methodologies or technologies?
(4) Investigator: Is the investigator appropriately trained and well suited
to carry out this work? Is the work proposed appropriate to the experience
level of the principal investigator and other researchers (if any)?
(5) Environment: Does the scientific environment in which the work will be
done contribute to the probability of success? Do the proposed experiments
take advantage of unique features of the scientific environment or employ
useful collaborative arrangements? Is there evidence of institutional
support? Has the support required of CTN participants been obtained so that
the proposed project is feasible?
In addition to the above criteria, in accordance with NIH policy, all
applications will also be reviewed with respect to the following:
The adequacy of plans to include both genders, minorities, and their
subgroups, and children as appropriate for the scientific goals of the
research. Plans for the recruitment and retention of subjects will also be
evaluated.
The adequacy of plans to make data available to other investigators in a
timely fashion.
The reasonableness of the proposed budget and duration in relation to the
proposed research.
The adequacy of the proposed protection for humans, animals, or the
environment, to the extent they may be adversely affected by the project
proposed in the application.
Schedule:
Letter of Intent: November 20, 2000
Application Receipt Date: December 19, 2000
Council Review: May 2001
Earliest Start Date: July 2001
AWARD CRITERIA
Award criteria that will be used to make award decisions include: scientific
merit as determined by peer review, availability of funds, and programmatic
priorities.
INQUIRIES
Inquiries concerning this RFA are strongly encouraged. The opportunity to
clarify issues or questions from potential applicants is welcome.
Direct inquires regarding programmatic issues to:
Bennett W. Fletcher, Ph.D.
Division of Epidemiology, Services,
and Prevention Research
National Institute on Drug Abuse
6001 Executive Boulevard, Room 4222, MSC 9565,
Bethesda, MD 20892-9565
Telephone: (301) 443-4060
FAX: (301) 443-6815
Email: bfletche@nida.nih.gov
Direct inquiries regarding fiscal matters to:
Jack Manischewitz, Ph.D.
Grants Management Branch, OPRM
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3131, MSC 9541
Bethesda, MD 20892-9541
Telephone: (301) 443-6710
FAX: (301) 594-6849
Email: jmanisch@nida.nih.gov
Direct inquiries regarding review issues to:
Teresa Levitin, Ph.D.
Office of Extramural Affairs
National Institute on Drug Abuse
6001 Executive Boulevard, Room 3158, MSC 9547
Bethesda, MD 20892-9547
Telephone: (301) 443-2755
FAX: (301) 443-0538
Email: tlevitin@nida.nih.gov
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance No.
93.279. Awards are made under authorization of Sections 301 and 405 of the
Public Health Service Act as amended (42 USC 241 and 284) and administered
under NIH grants policies and Federal Regulations 42 CFR Part 52 and CFR Part
74 and 92. This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and promote the non-use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
Department of Health and Human Services (HHS)
|
|
|
|
NIH... Turning Discovery Into Health®
|